Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis
| Autor: | S. Abogunrin, Ajibade Ashaye, Sandy Srinivas, Despina Thomaidou, Joseph C. Cappelleri, Lucile Serfass, Krishnan Ramaswamy, Giovanni Zanotti, Kyle Fahrbach, Andrew Clair |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Antineoplastic Agents Drug Administration Schedule law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Dosing schedules law Renal cell carcinoma Internal medicine Sunitinib medicine Humans Dosing Neoplasm Metastasis Adverse effect Carcinoma Renal Cell Protein Kinase Inhibitors Neoplasm Staging Clinical Trials as Topic business.industry Bayes Theorem General Medicine medicine.disease Kidney Neoplasms Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Meta-analysis Female Observational study business Publication Bias medicine.drug |
| Zdroj: | Future Oncology. 15:2175-2190 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2018-0858 |
| Popis: | The optimal dosing schedule to maintain the effectiveness of sunitinib for metastatic renal cell carcinoma – while reducing toxicity – remains an important clinical question. A meta-analysis of randomized trials and observational studies assessed the relative treatment effects of 4/2, 2/1 and transitional-2/1 schedules on outcomes and adverse events using Bayesian network meta-analysis methods. Treatment with 2/1 reduced the risk of disease progression or death by 25% and had lower odds of hand-and-foot syndrome compared with the 4/2. A numerical but not ‘statistical’ benefit in progression-free survival was observed with the transitional-2/1 compared with 4/2. Alternative schedules with the 2/1 and transitional-2/1 may be more clinically beneficial in metastatic renal cell carcinoma than the 4/2 schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|